Home › Bladder Cancer › New York › Albany
Bladder Cancer clinical trials in Albany, NY
4 studies for Bladder Cancer are looking for participants at sites in and around Albany (within about 30 miles). Open a study to see who can join and how to contact the study team.
Recruiting for a study here? Feature it at the top of this page — $99 for 30 days →
Symbiotic-GU-06: A Study to Learn About PF-08634404 Alone or In Combination With Enfortumab Vedotin in Urothelial Cancer
RecruitingPhase 1/2
- New York Oncology Hematology, Albany
LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve
RecruitingPhase 1/2
- Albany Medical College, Albany
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
RecruitingPhase 3
- Research Site, Albany
Study to Assess the Impact of the Urine Test Cxbladder Triage Plus on the Number of Cystoscopies Performed on Patients With Invisible Blood in Their Urine.
Recruiting
- Albany MED Health System, Albany
About Bladder Cancer
Bladder cancer symptoms range from lower back pain to blood in your urine. Read about important risk factors and find a list of treatments available
More about Bladder Cancer on MedlinePlus
Bladder Cancer trials in other cities
- New York City, NY35 studies
- Nashville, TN31 studies
- Houston, TX31 studies
- Dallas, TX27 studies
- Boston, MA26 studies
- Washington, DC26 studies
- Los Angeles, CA24 studies
- Baltimore, MD24 studies
- St. Louis, MO22 studies
- Philadelphia, PA21 studies
- Seattle, WA21 studies
- Edison, NJ21 studies
Other studies in Albany
- Non-Small Cell Lung Cancer9 studies
- Cardiovascular Disease7 studies
- Obesity6 studies
- Heart Failure6 studies
- Cancer (all types)5 studies
- Burkitt Lymphoma4 studies
- High Blood Pressure4 studies
- Metastatic Cancer4 studies
- Prostate Cancer4 studies
- Multiple Myeloma4 studies
- Digestive Diseases4 studies
- Breast Cancer4 studies
From ClinicalTrials.gov, data retrieved Oct 5, 2026. Each study sets its own eligibility; the study team decides who can join.